Gene-Silencing shot aims to quiet hepatitis b for good
Disease control
Recruiting now
This early-stage trial tests a new therapy called CRMA-1001, which uses epigenetic gene silencing to turn off the hepatitis B virus in the body. About 66 adults with chronic hepatitis B who are already on antiviral pills will receive one or more IV infusions of the therapy. The m…
Phase: PHASE1, PHASE2 • Sponsor: nChroma Bio • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC